| Followers | 1129 |
| Posts | 32627 |
| Boards Moderated | 2 |
| Alias Born | 01/11/2016 |
Friday, March 08, 2019 1:12:47 PM
It's due, if the results aren't good the we are out of luck, however why else they are going to release the data at the end of the month or first week of next month.
Recent CRDF News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:16:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:15:28 PM
- Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer • GlobeNewswire Inc. • 03/20/2026 11:00:00 AM
- Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 03/19/2026 11:00:00 AM
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 01:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 10:09:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 10:07:45 PM
- Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/19/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:02:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:01:02 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2026 09:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/27/2026 09:01:24 PM
- Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC • GlobeNewswire Inc. • 01/27/2026 12:05:00 PM
- Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development • GlobeNewswire Inc. • 01/27/2026 12:00:00 PM
- GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era • GlobeNewswire Inc. • 12/12/2025 03:31:03 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 • GlobeNewswire Inc. • 12/08/2025 09:05:00 PM
- Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference • GlobeNewswire Inc. • 12/08/2025 12:00:00 PM
- Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 09:08:38 PM
- Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update • GlobeNewswire Inc. • 11/06/2025 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:00:49 PM
- Cardiff Oncology to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 11/04/2025 09:01:00 PM
